Program
MODAG-005
A development code. Also written as “[11C]MODAG-005”.
Its studies are mostly in Parkinson Disease, led by MODAG.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MODAG | 11 open or running | early phase 1since May 24, 2026 | May 24, 2026 | Jul 2027early phase 1 · NCT07640542 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 24, 2026First study: early phase 1 study in Parkinson DiseaseFirst studyNCT07640542 · 9 planned · Germany
Ahead
- Jul 2027Primary completion: early phase 1 study in Parkinson DiseaseNCT07640542
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07640542Parkinson Disease · Germany | Early 1 | Recruiting | Jul 2027 | 9 |
How it is read
Names in the registry
- “[11C]MODAG-005”, 1 entry
Codes read as this program: MODAG005.
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.